Thymosin Alpha-1
Last reviewed 2026-10-30
Our read Opinion
Human trials exist, but evidence varies substantially by disease. The December 2024 FDA advisory committee voted against adding thymosin alpha-1 forms to the 503A bulks list.
- Type
- Approved outside US
- Regulatory status
- Approved outside US; not FDA-approved
- Compounding status
- Not cleared (advisory panel rejected)
- FDA-approved indications
- None
- Evidence level
- Human RCTs (approved use)
- Routes studied
- —
- WADA
- Verify
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to support immune defense
Synthetic counterpart of an endogenous thymic peptide that modulates dendritic-cell and T-cell responses. Toll-like-receptor signaling is implicated in its immunomodulatory effects.
Thymalfasin is approved outside the US, including China, for hepatitis-related indications; indications vary by jurisdiction. It is not FDA-approved, and foreign approval does not authorize US compounded products.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
0 news items in last 30 days
This has a more substantial clinical history than most wellness peptides. That history should not be generalized into evidence for immune boosting or longevity in healthy people.
No news yet for this peptide.
Stronger immune defense, faster recovery from infections, and support for chronic infections or mold illness.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.